NovaBay Pharmaceuticals (NBY) 10-Q 15 May 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 13, 2019
Document Information [Line Items]
Entity Registrant Name	NOVABAY PHARMACEUTICALS, INC.
Entity Central Index Key	0001389545
Trading Symbol	nby
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		18,992,116
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,932	$ 3,183
Accounts receivable, net of allowance for doubtful accounts ($24 and $10 at March 31, 2019 and December 31, 2018, respectively)	2,430	3,385
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($110 and $104 at March 31, 2019 and December 31, 2018, respectively)	302	280
Prepaid expenses and other current assets	1,451	1,760
Total current assets	7,115	8,608
Operating lease right-of-use assets	1,870
Property and equipment, net	193	201
Other assets	542	552
TOTAL ASSETS	9,720	9,361
Current liabilities:
Accounts payable	462	551
Accrued liabilities	2,860	3,255
Deferred revenue		41
Operating lease liability	1,073
Notes payable, related party	1,019
Total current liabilities	5,414	3,847
Operating lease liabilities-non-current	1,143
Deferred rent		184
Warrant liability	179	178
Convertible note	1,227
Embedded derivative liability associated with the convertible note	427
Other liabilities	201	198
Total liabilities	8,591	4,407
Stockholders' equity:
Preferred stock: 5,000 shares authorized; none outstanding at March 31, 2019 and December 31, 2018	0	0
Common stock, $0.01 par value; 50,000 shares authorized; 17,095 and 17,089 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively	171	171
Additional paid-in capital	120,484	119,764
Accumulated deficit	(119,526)	(114,981)
Total stockholders' equity	1,129	4,954
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 9,720	9,361
Previously Reported [Member]
Current liabilities:
Deferred revenue		$ 41

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Accounts receivable, allowance for doubtful accounts	$ 24	$ 10
Inventory, allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments	$ 110	$ 104
Preferred stock, shares authorized (in shares)	5,000	5,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	50,000	240,000
Common stock, shares issued (in shares)	17,095	17,089
Common stock, shares outstanding (in shares)	17,095	17,089

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Sales:
Total sales, net	$ 1,491	$ 2,947
Product cost of goods sold	341	251
Gross profit	1,150	2,696
Research and development	85	46
Sales and marketing	3,531	3,396
General and administrative	1,605	1,622
Total operating expenses	5,221	5,064
Operating loss	(4,071)	(2,368)
Non cash (loss) gain on changes in fair value of warrant liability	(57)	214
Other (expense) income, net	60	(4)
Loss before provision for income taxes	(4,188)	(2,150)
Provision for income tax	(1)
Net loss and comprehensive loss	$ (4,189)	$ (2,150)
Net loss per share attributable to common stockholders (basic) (in dollars per share)	$ (0.25)	$ (0.13)
Net loss per share attributable to common stockholders (diluted) (in dollars per share)	$ (0.25)	$ (0.14)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic) (in shares)	17,093	16,406
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (diluted) (in shares)	17,093	16,670
Product [Member]
Sales:
Total sales, net	$ 1,450	$ 2,934
Product and Service, Other [Member]
Sales:
Total sales, net	$ 41	$ 13

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating activities:
Net loss	$ (4,189)	$ (2,150)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	17	41
Impairment of operating lease right-of-use assets	125
Stock option modification expense		77
Issuance of RSUs to employees	10
Non-cash loss (gain) on change in fair value of warrant liability	57	(214)
Amortization of debt issuance and debt discount	20
Amortization of debt issuance related to related party notes payable	5
Changes in operating assets and liabilities:
Accounts receivable	954	1,934
Inventory	(21)
Prepaid expenses and other assets	214	(88)
Operating lease right-of-use assets	244
Other assets long-term	10	17
Accounts payable and accrued liabilities	(521)	(161)
Operating lease liabilities	(256)
Deferred rent		(16)
Deferred revenue	(41)	(13)
Related party notes payable	34
Long-term obligations	3
Net cash (used) in operating activities	(3,221)	(464)
Investing activities:
Purchases of property and equipment	(14)	(2)
Net cash (used) by investing activities	(14)	(2)
Financing activities:
Proceeds from common stock issuances, net		5,591
Proceeds from issuance of notes payable, related party, net of issuance cost	980
Proceeds from exercise of options, net	0	11
Proceeds from stock options & RSUs sold to cover taxes	4	1
Proceeds from convertible notes, net of discount	2,000
Net cash provided by investing activities	2,984	5,603
Net (decrease) increase in cash, cash equivalents, and restricted cash	(251)	5,137
Cash, cash equivalents and restricted cash, beginning of period	3,658	3,673
Cash, cash equivalents and restricted cash, end of period	3,407	8,810
Cumulative effect of adoption of New ASU		2,638
Addition of operating lease, right-of-use asset	2,473
Fixed asset purchases, included in accounts payable and accrued liabilities	(5)	3
Proceeds from stock options and restricted stock for taxes, in accounts payable and accrued liabilities		1
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense for options and stock issued	107	102
Nonemployees [Member] | Share-based Payment Arrangement, Option [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense for options and stock issued	7	7
Accounting Standards Update 2014-09 [Member]
Financing activities:
Cumulative effect of adoption of New ASU		2,638
Accounting Standards Update 2017-11 [Member]
Financing activities:
Cumulative effect of adoption of New ASU	$ 56

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Employee [Member]Common Stock [Member]	Employee [Member]Additional Paid-in Capital [Member]	Employee [Member]AOCI Attributable to Parent [Member]	Employee [Member]Retained Earnings [Member]	Employee [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017						15,385,000
Balance at Dec. 31, 2017						$ 154	$ 113,514		$ (111,074)	$ 2,594
Net loss									(2,150)	(2,150)
Stock-based compensation expense related to employee and director stock options							102			102
Stock-based compensation expense related to non-employee and director stock options							7			7
Issuance of common stock in connection with offering (in shares)						1,700,000
Issuance of common stock in connection with offering						$ 17	5,967			5,984
Offering costs							(393)			$ (393)
Issuance of stock for option exercises (in shares)						4,000				4,000
Issuance of stock for option exercises							11			$ 11
Adoption of ASC 606									2,638	2,638
Stock option modification							77			77
Balance (in shares) at Mar. 31, 2018						17,089,000
Balance at Mar. 31, 2018						$ 171	119,285		(110,586)	8,870
Balance (in shares) at Dec. 31, 2018						17,089,000
Balance at Dec. 31, 2018						$ 171	119,764		(114,981)	4,954
Net loss									(4,189)	(4,189)
Reclassification of Warrant Liability to Equity – see note 2							412		(356)	56
Vesting of restricted stock awards (in shares)	6,000
Vesting of restricted stock awards		$ 10			$ 10
Stock-based compensation expense related to employee and director stock options							107			107
Stock-based compensation expense related to non-employee and director stock options							7			7
Debt discount associated with the convertible note – beneficial conversion feature							184			184
Balance (in shares) at Mar. 31, 2019						17,095,000
Balance at Mar. 31, 2019						$ 171	$ 120,484		$ (119,526)	$ 1,129

Note 1 - Organization

Note 1 - Organization	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1. NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two ® ® ® ® ® The Company was incorporated under the laws of the State of California on January 19, 2000, no July 1, 2002, February 2007, June 2010, four April 2016, Effective December 18, 2015, 1 25 Liquidity Based primarily on the funds available at March 31, 2019, second 2019. 2019 2019 may 1 2 3 one 4 may 1 3 one one not may

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates. Unaudited Interim Financial Information The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not not Cash , Cash Equivalents , and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three March 31, 2019 December 31, 2018, two Beginning fiscal 2018, No. 2016 18, Statement of Cash Flows (Topic 230 three March 31, 2019 2018 not The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the consolidated balance sheet that sum to the total of the same reported in the consolidated statement of cash flows: (in thousands) March 31, December 31, 2019 2018 Cash and cash equivalents $ 2,932 $ 3,183 Restricted cash included in Other assets 475 475 Total cash, cash equivalents, and restricted cash in the statement of cash flows $ 3,407 $ 3,658 The restricted cash amount included in Other assets on the consolidated balance sheet represents amounts held as certificate of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord. Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with two Deposits in these banks may not During the three March 31, 2019 2018, three During the three March 31, 2019 2018, 10% Three Months Ended March 31, Major distribution or collaboration partner 2019 2018 Distributer A 26 % 21 % Distributer B 14 % 27 % Distributer C 17 % 25 % As of March 31, 2019 December 31, 2018, 10% March 31, December 31, Major distribution or collaboration partner 2019 2018 Distributer A 41 % 32 % Distributer B 33 % 23 % Distributer C 13 % 31 % The Company relies on two not third may not Fair Value of Financial Assets and Liabilities The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, related party notes payable, convertible note, and warrants. The fair value of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, and related party notes payable is carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The convertible note issued in March 2019 ( The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures three may Level 1 Level 2 Level 3 Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and it believes are unlikely to be collected. As of March 31, 2019 December 31, 2018, $24 $10 120 Inventory Inventory is comprised of ( 1 2 3 March 31, 2019 December 31, 2018, $110 $104 Inventory is stated at the lower of cost or estimated net realizable value determined by the first first Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three seven seven The costs of normal maintenance, repairs, and minor replacements are charged to operations when incurred. Impairment of Long-Lived Assets and Operating Lease Right-of-Use Assets The Company accounts for long-lived assets and operating lease right-of-use assets in accordance with ASC 360, Property, Plant and Equipment may not first 2019, $125 8, no three March 31, 2018. Leases In February 2016, No. 2016 02, Leases (Topic 842 January 1, 2019. not At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not may The Company has elected to combine lease and non-lease components as a single component for all leases in which it is a lessee or a lessor. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. As a result, as of the effective date, the Company no Comprehensive Income (Loss) ASC 220 , Comprehensive Income , Revenue Recognition The Company generates product revenue through product sales to its major distribution partners, a limited number of distributors and via its webstore. Product supply is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon shipment to the distributer on a “sell-in” basis. Other revenue is primarily generated through commercial partner agreements with strategic partners for the development and commercialization of the Company’s product candidates. The terms of the agreements typically include more than one In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. ● Product supply ● Exclusive distribution rights in the product territory ● Regulatory submission and approval services ● Development services ● Sample supply, free of charge ● Incremental discounts and product supply prepayments considered material rights to the customer The Company has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer’s or the Company’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, such material rights are accounted for as separate performance obligations. Transaction Price The Company has both fixed and variable consideration. Under the Company’s license arrangements, non-refundable upfront fees and product supply selling prices are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point they are considered fixed. The Company allocates the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation. For product supply under the Company’s distribution arrangements, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, chargebacks, and product returns. Because the Company does not not 30 one one At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not not not For arrangements that include sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Allocation of Consideration As part of the accounting for arrangements that contain multiple performance obligations, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. When a contract contains more than one Timing of Recognition Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for products at a point in time and for licenses of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that the Company has incurred to perform the services using the cost-to-cost input method. The Company’s intellectual property in the form of distribution rights are determined to be distinct from the other performance obligations identified in the arrangements and considered “right to use” licenses which the customer can benefit from at a point in time. The Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer, and the customer can use and benefit from the license. Cost of Goods Sold Cost of goods sold includes third Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include salaries and benefits for research and development personnel, costs associated with clinical trials managed by contract research organizations, and other costs associated with research, development and regulatory activities. Research and development costs may no may Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Stock-Based Compensation The Company’s stock-based compensation includes grants of stock options and restricted stock units, or RSUs, to employees, consultants and non-employee directors. The expense associated with these programs is recognized in the Company’s consolidated statements of stockholders’ equity based on their fair values as they are earned under the applicable vesting terms or the length of an offering period. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes-Merton option pricing model. See Note 13 Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not Common Stock Warrant Liability For warrants that are newly issued or modified and there is a deemed possibility that the Company may On January 1, 2019, 2017 11, Earnings Per Share (Topic 260 480 815 2017 11 no no 2017 11, March 31, 2019 $56 $56 $356 January 1, 2019, $356 11 Net (Loss) per Share The Company computes net (loss) per share by presenting both basic and diluted (loss) per share (“EPS”). Basic EPS is computed by dividing net (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods since their effect would be anti-dilutive. During the three March 31, 2019, no three March 31, 2018, $0.13 $0.14 The following table sets forth the calculation of basic EPS and diluted EPS: (in thousands except per share) Three Months Ended March 31, Numerator 2019 2018 Net loss $ (4,189 ) $ (2,150 ) Less gain on changes in fair value of warrant liability — (214 ) Net loss, diluted $ (4,189 ) $ (2,364 ) Denominator Weighted average shares outstanding, basic 17,093 16,406 Net loss per share, basic $ (0.25 ) $ (0.13 ) Weighted average shares outstanding, basic 17,093 16,406 Effect of dilutive warrants — 264 Weighted average shares outstanding, diluted 17,093 16,670 Net loss per share, diluted $ (0.25 ) $ (0.14 ) The following outstanding stock options and stock warrants were excluded from the diluted net loss per share computation, as their effect would have been anti-dilutive: As of March 31, (in thousands) 2019 2018 Period end stock options to purchase common stock 2,389 2,433 Period end common stock warrants 544 — 2,933 2,433 Recent Accounting Pronouncements SEC Disclosure Regulation Simplifications During the fourth 2018, No. 33 10532, November 5, 2018, 2019 Leases In February 2016, No. 2016 02, Leases (Topic 842 12 2016 02 first 2019. 1 not 2 not 3 not not The adoption of the new leases standard resulted in the following adjustments to the consolidated balance sheet as of January 1, 2019 ( Prepaid expenses and other current assets (a) $ (49 ) Operating lease right-of-use assets 2,239 Other assets (b) (2 ) Other accrued liabilities (c) (101 ) Operating lease liability 1,063 Deferred rent (184 ) Operating lease liability - non-current 1,410 (a) Represents current portion of prepaid fleet leasing costs reclassified to Operating lease right-of-use assets . (b) Represents noncurrent portion of prepaid fleet leasing costs reclassified to Operating lease right-of-use assets. (c) Represents current portion of deferred rent and lease incentive liability reclassified to Operating lease liability. The adoption of the new leases standard did not January 1, 2019, In July 2017, 2017 11, Earnings Per Share (Topic 260 ), Distinguishing Liabilities from Equity (Topic 480 ), Derivatives and Hedging (Topic 815 ): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. 480 not December 15, 2018, 2017 11 January 1, 2019. 2017 11, March 31, 2019 January 1, 2019 ( 11 In June 2018, 2018 07, Compensation—Stock Compensation (Topic 718 2018 07 January 1, 2019, $2 In August 2018, 2018 13, Fair Value Measurement (Topic 820 December 15, 2019, not

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3. The Company follows ASC 820, Fair Value Measurements and Disclosures The Company's cash equivalents and investments are classified within Level 1 2 1 2 The Company's warrant liability is classified within Level 3 11, As a result of the call option and the put feature within the Convertible Note entered into in March 2019, 3 10, The following table presents the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2019: Fair Value Measurements Using (in thousands) Balance at March 31, 2019 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 103 $ 103 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 151 151 — — Total assets $ 578 $ 578 $ — $ — Liabilities Warrant liability $ 179 $ — $ — $ 179 Derivative liability 427 — — 427 Total liabilities $ 606 $ — $ — $ 606 The following table presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2018: Fair Value Measurements Using (in thousands) Balance at December 31, 2018 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 103 $ 103 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 151 151 — — Total assets $ 578 $ 578 $ — $ — Liabilities Warrant liability $ 178 $ — $ — $ 178 Total liabilities $ 178 $ — $ — $ 178 Upon adoption of ASU 2017 11, 210,586 no 334,109 $57 three March 31, 2019, 11, The following is a reconciliation of the beginning and ending balances for the liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3 three March 31, 2019: Level 3 (in thousands) liabilities Balance at December 31, 2018 $ 178 Fair value of warrant liability reclass to equity-Adoption of ASU 2017-11 (56 ) Increase in fair value of warrant liability at March 31, 2019 57 Embedded derivative liability associated with the convertible note 427 Fair value of warrant liability and embedded derivative liability at March 31, 2019 $ 606

Note 4 - Prepaid Expenses and O

Note 4 - Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Prepaid Expenses and Other Current Assets [Text Block]	NOTE 4. Prepaid expenses and other current assets consisted of the following: March 31, December 31, (in thousands) 2019 2018 Prepaid sales rebates $ 803 $ 925 Rent receivable 80 108 Prepaid rent — 130 Prepaid employees’ benefits 8 113 Prepaid dues and subscription 129 130 Inventory deposits 83 — Other 348 354 Total prepaid expenses and other current assets $ 1,451 $ 1,760

Note 5 - Inventory

Note 5 - Inventory	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Inventory Disclosure [Text Block]	N OTE 5. Inventory consisted of the following: March 31, December 31, (in thousands) 2019 2018 Raw materials and supplies $ 188 $ 217 Finished goods 224 167 Less: Reserve for excess and obsolete inventory (110 ) (104 ) Total inventory, net $ 302 $ 280

Note 6 - Property and Equipment

Note 6 - Property and Equipment	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 6. Property and equipment consisted of the following: March 31, December 31, (in thousands) 2019 2018 Office and laboratory equipment $ 24 $ 24 Furniture and fixtures 157 157 Computer equipment and software 394 385 Production equipment 65 65 Leasehold improvements 79 79 Total property and equipment, at cost 719 710 Less: accumulated depreciation and amortization (526 ) (509 ) Total property and equipment, net $ 193 $ 201 Depreciation and amortization expense was $17 $41 three March 31, 2019 2018,

Note 7 - Accrued Liabilities

Note 7 - Accrued Liabilities	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 7. Accrued liabilities consisted of the following: March 31, December 31, (in thousands) 2019 2018 Employee payroll and benefits $ 630 $ 708 Severance 124 — Avenova contract liabilities 1,816 2,282 Deferred rent — 101 Other 290 164 Total accrued liabilities $ 2,860 $ 3,255

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 8 . COMMITMENTS AND CONTINGENCIES Directors and Officers Indemnification As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may not March 31, 2019. In the normal course of business, the Company provides indemnification of varying scope under its agreements with other companies, typically its clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third not March 31, 2019. Legal Matters From time to time, the Company may no March 31, 2019, Leases The Company leases office space for its corporate headquarters, located in Emeryville, CA (“Office Lease”). The initial lease term is through February 28, 2022. one five 5 October 31, 2020. no not In July 2016, September 8, 2016. October 21, 2020 no not In addition to the facility leases, the Company has leased 54 36 first 2017. first 2019, $125 Additionally, the Company has an operating lease for 2 August 2019. not In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not not not The components of lease expense for the three March 31, 2019 Lease Costs Operating lease cost $ 312 Sublease income (158 ) Net lease cost $ 154 Other information Operational cash flow used for operating leases $ 324 Weighted-average remaining lease term (in years) 2.2 Weighted-average discount rate 12 % Future lease payments under non-cancelable leases as of March 31, 2019 Remaining in 2019 $ 970 2020 1,046 2021 438 2022 75 Thereafter — Total future minimum lease payments 2,529 Less imputed interest (313 ) Total $ 2,216 Reported as: Operating lease liability $ 1,073 Operating lease liability- non-current 1,143 Total $ 2,216 Future lease payments to be received under non-cancelable leases as of March 31, 2019 Remaining in 2019 $ 566 2020 577 2021 — 2022 — Thereafter — Total future minimum lease payments $ 1,143

Note 9 - Related Party Notes Pa

Note 9 - Related Party Notes Payable	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Related Party Notes Payable [Text Block]	NOTE 9. RELATED PARTY NOTES PAYABLE On February 27, 2019, $1.0 $150 no July 27, 2019. 2% one $100 $20 July 27, 2019. $39 three March 31, 2019. The Promissory Note is presented as follows as of March 31, 2019: (in thousands) Principle amount $ 1,000 Unamortized debt issuance costs (15 ) Accrued interst 34 Total debt 1,019 Less: short-term (1,019 ) Long-term $ —

Note 10 - Convertible Note

Note 10 - Convertible Note	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 10. CONVERTIBLE NOTE On March 26, 2019 ( $2,215,000, 10% September 26, 2020, $2.0 $200 $15 $182 not March 31, 2019. The Convertible Note provides the Lender with the right to convert, at any time, all or any part of the outstanding principal and accrued but unpaid interest into unregistered shares of the Company’s common stock at a conversion price of $1.65 September 26, 2019, $200 may $1.65 85% 20 may 115% The Company has reserved 3,200,000 Pursuant to a Security Agreement between the Company and the Lender, repayment of the Convertible Note is secured by all of the assets of the Company. The assets covered by the Security Agreement are currently encumbered by that certain lien of up to $1.0 The Convertible Note contains events of default upon the occurrence and during the continuance of which all obligations may 15%, The Company’s prepayment terms represent an embedded call option, the Lender’s share redemption terms represent an embedded put option and certain events of default also represent embedded derivatives, each of which require bifurcation. A single derivative comprising all bifurcatable features was measured at fair value using a Monte Carlo simulation. The key assumptions used to value the combined embedded derivative as of March 26, 2019 As of Assumption March 26, 2019 Stock price (latest bid price) $ 1.28 Equity volatility 93.8 % Risk-free interest rate 2.34 % Remaining term 1.5 The fair value of the combined embedded derivative was $427 March 26, 2019 March 26, 2019 March 31, 2019. The effective conversion rate of the debt, taking into consideration the original issue discount and the value of the combined embedded derivative, was lower than the fair value of the Company’s common stock as of the Closing Date, resulting in a beneficial conversion feature (“BCF”). The Company recorded the intrinsic value of the BCF of $184 The aggregate $811 $197 March 31, 2019: (in thousands) Principle amount $ 2,215 Unamortized discount (795 ) Unamortized debt issuance costs (193 ) Total debt 1,227 Less: short-term — Long-term $ 1,227 The Convertible Note is classified as long-term based on the Company intent and ability to issue shares of its common stock upon early redemption by the Lender. The discount and debt issuance costs are being amortized to interest expense using the effective interest rate method over the term of the Convertible Note, assuming that the Convertible Note will be redeemed at the maximum $200 September 2019. three March 31, 2019, 64% $24 As of March 31, 2019, (in thousands) Remainder of 2019 $ — 2020 2,215 2021 and thereafter — Total $ 2,215

Note 11 - Warrant Liability

Note 11 - Warrant Liability	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	NOTE 1 1 . WARRANT LIABILITY In July 2011, 139,520 $33.25 January 1, 2012 July 5, 2016. 480, Distinguishing Liabilities from Equity 480 January 5, 2012, $66.50 ten not fifteen one third In October 2015, March 3, 2015 ( “2015 twenty two March 3, 2016). October 2015 15 five 2015 “March 2015 June 29, 2011 ( “July 2011 March 2015 July 2011 $5.00 July 2011 March 6, 2020. July 2011 March 2015 $5.00 $5.00, In October 2015, 492,000 442,802 “October 2015 $5.00 “October 2015 60 October 2015 $5.00 $2.1 In February 2016, July 2011, March 2015 October 2015 $1.81 The key assumptions used to value the July 2011 March 31, 2019 December 31, 2018 As of March 31, December 31, Assumption 2019 2018 Expected price volatility 104 % 77 % Expected term (in years) 0.93 1.18 Risk-free interest rate 2.41 % 2.60 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 0.45 $ 0.29 In March 2015, $15.00 $16.25 not March 2015 July 2011 October 2015, March 2015 March 2015 October 27, 2015 $1.8 October 27, 2015 October 27, 2015. As described in Note 2, 2017 11, March 31, 2019 $56 $56 $356 January 1, 2019, $356 The key assumptions used to value the Short-Term Warrants as of December 31, 2018 As of December 31, Assumption 2018 Expected price volatility 77 % Expected term (in years) 1.18 Risk-free interest rate 2.60 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 0.24 The key assumptions used to value the Long-Term Warrants as of December 31, 2018 As of December 31, Assumption 2018 Expected price volatility 77 % Expected term (in years) 1.18 Risk-free interest rate 2.60 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 0.29 As noted above, the Company issued warrants in connection with the October 2015 October 2015 480, 480 October 27, 2015 $1.3 The key assumptions used to value the October 2015 March 31, 2019 December 31, 2018 As of March 31, December 31, Assumption 2019 2018 Expected price volatility 93 % 73 % Expected term (in years) 1.58 1.83 Risk-free interest rate 2.33 % 2.51 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 0.55 $ 0.38 During the third 2016, 3,613,284 3,613,284 July 2011, March 2015 October 2015, $6.9 $1.6 $1.6 During the fourth 2016, 363,523 363,523 October 2011, November 2015 December 2015 $0.9 $0.5 $0.5 During the second 2017, 21,000 21,000 March 2015 $38 $58 $58 The details of the outstanding warrant liability as of March 31, 2019, Warrant Shares and dollars in thousands Shares Liability July 2011 Warrants 49 $ 23 October 2015 Warrants 284 156 333 $ 179

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 1 2 . STOCKHOLDERS’ EQUITY Preferred Stock Under the Company’s amended articles of incorporation, the Company is authorized to issue up to 5,000,000 may March 31, 2019 December 31, 2018, no Common Stock During the first 2018, 1,700,000 $0.01 $5,984,000 February 8, 2018. six 6% $359,040. $34 On March 29, 2019, $3,000,000 90% five March 29, 2019 3 April 1, 2019 April 12, 2019. 150,000 Stock Warrants In February 2016, July 2011, March 2015 October 2015 $1.81 As more fully described in Note 3, 210,586 2017 11, $56 $56 $356 January 1, 2019. The details of all outstanding warrants as of March 31, 2019, Weighted- Average Exercise (in thousands) Warrants Price Outstanding at December 31, 2018 544 $ 1.81 Warrants granted — $ — Warrants exercised — $ — Warrants expired — $ — Outstanding at March 31, 2019 544 $ 1.81

Note 13 - Equity-based Compensa

Note 13 - Equity-based Compensation	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	NOTE 1 3 . EQUITY-BASED COMPENSATION Equity Compensation Plans In October 2007, 2007 “2007 2007 40,000 2007 For the years from 2009 2012, 2007 40,000 4% 40,000, 37,427, 37,207 2007 January 2012, 2011 2010, 2013, 40,000 2007 4% 32,646 59,157 2007 January 2014 2013, March 30, 2015, 82,461 2007 January 2016, 139,449 2007 2007 May 26, 2016, 2007 1,124,826 January 2017, 610,774 2007 2007 2007 2,318,486 March 15, 2017 ( 2007 Upon expiration of the 2007 2007 March 15, 2017 2007 may not 100% 10% not 110% 2007 no ten four In March 2017, 2017 “2017 June 2, 2017, 2017 not 2007 2017 2,318,486 first January 1, 2018 January 1, 2027 four 4 2017 March 31, 2019, 1,932,623 2017 Under the terms of the 2017 may not 100% 10% not 110% not ten not five ten four 2007 2017 Stock Option Summary The following table summarizes information about the Company’s stock options outstanding at March 31, 2019, three (in thousands, except years and per share data) Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2018 3,374 $ 4.13 8.2 $ 8 Restricted stock units vested (6 ) $ — Options forfeited/cancelled (978 ) $ 2.66 Restricted stock units cancelled (1 ) $ — Outstanding at March 31, 2019 2,389 $ 4.75 7.7 $ 6 Vested and expected to vest at March 31, 2019 2,355 $ 4.78 7.7 $ 5 Vested at March 31, 2019 1,725 $ 5.71 7.3 $ — Exercisable at March 31, 2019 1,725 $ 5.71 7.3 $ — For options that have a quoted market price in excess of the exercise price (“in-the-money options”), the aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company’s common stock as quoted on the NYSE American as of March 31, 2019. no three March 31, 2019. no three March 31, 2019. 4 three March 31, 2018 $11 $5 three March 31, 2018. As of March 31, 2019, $823 2.79 Stock Option Awards to Employees and Directors The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes-Merton option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2, During the three March 31, 2019 March 31, 2018, not When the Company grants stock options, the stock options are recorded at their fair value on the grant date and recognized over the respective service or vesting period. The fair value of the stock options that are granted is calculated using the Black-Scholes-Merton option pricing model using the following assumptions: Expected Price Volatility Expected Term Risk-Free Interest Rate Dividend Yield not Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. In addition, during the three March 31, 2019 2018, not For the three March 31, 2019 2018, $107 $179 In March 2018, March 21, 2018. three three $26 Stock-Based Awards to Non-Employees for Advising and Consulting Services During the three March 31, 2019 March 31, 2018, not When the Company grants stock options, the stock options are recorded at their fair value on the grant date and recognized over the respective service or vesting period. The fair value of the stock options that are granted is calculated using the Black-Scholes-Merton option pricing model as discussed above. In addition, during the three March 31, 2019 2018, not For the three March 31, 2019 2018, $7 Summary of Stock-Based Compensation Expense A summary of stock-based compensation expense included in results of operations for the option and stock awards discussed above is as follows: Three Months Ended March 31, (in thousands) 2019 2018 Research and development $ 11 $ 7 Sales and Marketing 19 34 General and administrative 84 145 Total stock-based compensation expense $ 114 $ 186 Since the Company has operating losses and net operating loss carryforwards, there are no

Note 14 - License, Collaboratio

Note 14 - License, Collaboration and Distribution Agreements	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
License, Collaboration, and Distribution Agreements [Text Block]	NOTE 14. Transactions under the Company's major distribution agreements are recognized upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the invoiced amounts that are estimated to be subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, chargebacks, and product returns. Milestone payments are included in the estimated transaction price when they are considered probable of being achieved. For license and collaboration revenue, the transaction price under license and collaboration arrangements, including upfront fees and milestone payments, are allocated differently to each performance obligation and may The following table presents changes in the Company's contract assets and liabilities for the three March 31, 2019: Balance at Beginning of the Period Additions Deductions Balance at the end of the Period (in thousands) Contract Liabilities: Deferred Revenue $ 41 $ — $ (41 ) $ — Contract Liabilities: Accrued Liabilities 1,432 2,664 (3,029 ) 1,067 Total $ 1,473 $ 2,664 $ (3,070 ) $ 1,067 During the three March 31, 2019 2018, Three Months Ended March 31, 2019 2018 Revenue recognized in the period from: Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 1,444 $ 1,439 New activities in the period: Performance obligations satisfied 47 1,508 $ 1,491 $ 2,947 License , Collaboration and Distribution Agreements In January 2012, $312,500. $312,500 January 2013, first December 31, 2014, $625,000 In September 2012, two 1 2 one one Pursuant to the terms of the Distribution Agreement, China Pioneer has the right to distribute NeutroPhase, upon a marketing approval from a Regulatory Authority, in certain territories in Asia (other than China). Upon execution of the Distribution Agreement, the Company received an upfront payment, which was recorded as deferred revenue. China Pioneer is also obligated to make certain additional payments to the Company upon receipt of the marketing approval. The Distribution Agreement further provides that China Pioneer is entitled to a cumulative purchase discount not $500,000 Pursuant to the Purchase Agreement, we also received $2.5 one one two 1 800,000 September 2012; 2 1,200,000 October 2012, $1.25 $3.5 $2.5 $1.0 $600,000 In December 2013, 11 On February 7, 2012, $750,000. In April 2013, 422 $250,000. On June 1, 2013, $200,000. During the three March 31, 2019, $41 three March 31, 2018, $13 $0 $41 March 31, 2019 December 31, 2018, Avenova Distribution Agreements In November 2014, January 2015, April 2015, During the three March 31, 2019 2018, $1.2 $2.6 Under the Avenova product distribution arrangements, the Company had a contract liability balance of $1.1 $1.4 March 31, 2019 December 31, 2018, March 31, 2019 December 31, 2018 $0.8 $0.9 4

Note 15 - Employee Benefit Plan

Note 15 - Employee Benefit Plan	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 1 5 . EMPLOYEE BENEFIT PLAN The Company has a 401 not no three March 31, 2019 2018.

Note 16 - Related Party Transac

Note 16 - Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 1 6 . RELATED PARTY TRANSACTIONS Related Party Financing See Note 9, February 27, 2019. Related Party Revenue The Company recognized related party revenues from product sales and license and collaboration fees of $41 $13 three March 31, 2019 2018, $0 $219 three March 31, 2019 2018. $6 $39 March 31, 2019 December 31, 2018, 14, second Related Party Expenses The Company paid related party fees of $70 $359 three March 31, 2019 2018, $20 three March 31, 2019 three March 31, 2019, $4 $50 March 11, 2019. $8 three March 31, 2019. 9, three March 31, 2018 12,

Note 17 - Subsequent Events

Note 17 - Subsequent Events	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 17. On March 29, 2019, $3,000,000 90% five March 29, 2019 3 April 1, 2019 April 12, 2019. 150,000 Pursuant to the Common Stock Purchase Agreement, on April 22, 2019, 1,747,312 April 22, 2019 9.99% May 13, 2019, 1,747,312 $0.37089 $648,060.55. Separately, on April 12, 2019, not 1003 $6.0 five 1009 May 12, 2019 1003 October 12, 2020.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates.
Unaudited Interim Financial Information, Policy [Policy Text Block]	Unaudited Interim Financial Information The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash , Cash Equivalents , and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three March 31, 2019 December 31, 2018, two Beginning fiscal 2018, No. 2016 18, Statement of Cash Flows (Topic 230 three March 31, 2019 2018 not The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the consolidated balance sheet that sum to the total of the same reported in the consolidated statement of cash flows: (in thousands) March 31, December 31, 2019 2018 Cash and cash equivalents $ 2,932 $ 3,183 Restricted cash included in Other assets 475 475 Total cash, cash equivalents, and restricted cash in the statement of cash flows $ 3,407 $ 3,658 The restricted cash amount included in Other assets on the consolidated balance sheet represents amounts held as certificate of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with two Deposits in these banks may not During the three March 31, 2019 2018, three During the three March 31, 2019 2018, 10% Three Months Ended March 31, Major distribution or collaboration partner 2019 2018 Distributer A 26 % 21 % Distributer B 14 % 27 % Distributer C 17 % 25 % As of March 31, 2019 December 31, 2018, 10% March 31, December 31, Major distribution or collaboration partner 2019 2018 Distributer A 41 % 32 % Distributer B 33 % 23 % Distributer C 13 % 31 % The Company relies on two not third may not
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Assets and Liabilities The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, related party notes payable, convertible note, and warrants. The fair value of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, and related party notes payable is carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The convertible note issued in March 2019 ( The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures three may Level 1 Level 2 Level 3 Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and it believes are unlikely to be collected. As of March 31, 2019 December 31, 2018, $24 $10 120
Inventory, Policy [Policy Text Block]	Inventory Inventory is comprised of ( 1 2 3 March 31, 2019 December 31, 2018, $110 $104 Inventory is stated at the lower of cost or estimated net realizable value determined by the first first
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three seven seven The costs of normal maintenance, repairs, and minor replacements are charged to operations when incurred.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets and Operating Lease Right-of-Use Assets The Company accounts for long-lived assets and operating lease right-of-use assets in accordance with ASC 360, Property, Plant and Equipment may not first 2019, $125 8, no three March 31, 2018.
Lessee, Leases [Policy Text Block]	Leases In February 2016, No. 2016 02, Leases (Topic 842 January 1, 2019. not At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not may The Company has elected to combine lease and non-lease components as a single component for all leases in which it is a lessee or a lessor. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. As a result, as of the effective date, the Company no
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) ASC 220 , Comprehensive Income ,
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company generates product revenue through product sales to its major distribution partners, a limited number of distributors and via its webstore. Product supply is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon shipment to the distributer on a “sell-in” basis. Other revenue is primarily generated through commercial partner agreements with strategic partners for the development and commercialization of the Company’s product candidates. The terms of the agreements typically include more than one In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. ● Product supply ● Exclusive distribution rights in the product territory ● Regulatory submission and approval services ● Development services ● Sample supply, free of charge ● Incremental discounts and product supply prepayments considered material rights to the customer The Company has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer’s or the Company’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, such material rights are accounted for as separate performance obligations. Transaction Price The Company has both fixed and variable consideration. Under the Company’s license arrangements, non-refundable upfront fees and product supply selling prices are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point they are considered fixed. The Company allocates the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation. For product supply under the Company’s distribution arrangements, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, chargebacks, and product returns. Because the Company does not not 30 one one At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not not not For arrangements that include sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Allocation of Consideration As part of the accounting for arrangements that contain multiple performance obligations, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. When a contract contains more than one Timing of Recognition Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for products at a point in time and for licenses of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that the Company has incurred to perform the services using the cost-to-cost input method. The Company’s intellectual property in the form of distribution rights are determined to be distinct from the other performance obligations identified in the arrangements and considered “right to use” licenses which the customer can benefit from at a point in time. The Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer, and the customer can use and benefit from the license.
Cost of Goods Sold, Policy [Policy Text Block]	Cost of Goods Sold Cost of goods sold includes third
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include salaries and benefits for research and development personnel, costs associated with clinical trials managed by contract research organizations, and other costs associated with research, development and regulatory activities. Research and development costs may no may
Patent Costs Policy [Policy Text Block]	Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss.
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company’s stock-based compensation includes grants of stock options and restricted stock units, or RSUs, to employees, consultants and non-employee directors. The expense associated with these programs is recognized in the Company’s consolidated statements of stockholders’ equity based on their fair values as they are earned under the applicable vesting terms or the length of an offering period. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes-Merton option pricing model. See Note 13
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not
Warrant Liabilities [Policy Text Block]	Common Stock Warrant Liability For warrants that are newly issued or modified and there is a deemed possibility that the Company may On January 1, 2019, 2017 11, Earnings Per Share (Topic 260 480 815 2017 11 no no 2017 11, March 31, 2019 $56 $56 $356 January 1, 2019, $356 11
Earnings Per Share, Policy [Policy Text Block]	Net (Loss) per Share The Company computes net (loss) per share by presenting both basic and diluted (loss) per share (“EPS”). Basic EPS is computed by dividing net (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods since their effect would be anti-dilutive. During the three March 31, 2019, no three March 31, 2018, $0.13 $0.14 The following table sets forth the calculation of basic EPS and diluted EPS: (in thousands except per share) Three Months Ended March 31, Numerator 2019 2018 Net loss $ (4,189 ) $ (2,150 ) Less gain on changes in fair value of warrant liability — (214 ) Net loss, diluted $ (4,189 ) $ (2,364 ) Denominator Weighted average shares outstanding, basic 17,093 16,406 Net loss per share, basic $ (0.25 ) $ (0.13 ) Weighted average shares outstanding, basic 17,093 16,406 Effect of dilutive warrants — 264 Weighted average shares outstanding, diluted 17,093 16,670 Net loss per share, diluted $ (0.25 ) $ (0.14 ) The following outstanding stock options and stock warrants were excluded from the diluted net loss per share computation, as their effect would have been anti-dilutive: As of March 31, (in thousands) 2019 2018 Period end stock options to purchase common stock 2,389 2,433 Period end common stock warrants 544 — 2,933 2,433
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements SEC Disclosure Regulation Simplifications During the fourth 2018, No. 33 10532, November 5, 2018, 2019 Leases In February 2016, No. 2016 02, Leases (Topic 842 12 2016 02 first 2019. 1 not 2 not 3 not not The adoption of the new leases standard resulted in the following adjustments to the consolidated balance sheet as of January 1, 2019 ( Prepaid expenses and other current assets (a) $ (49 ) Operating lease right-of-use assets 2,239 Other assets (b) (2 ) Other accrued liabilities (c) (101 ) Operating lease liability 1,063 Deferred rent (184 ) Operating lease liability - non-current 1,410 (a) Represents current portion of prepaid fleet leasing costs reclassified to Operating lease right-of-use assets . (b) Represents noncurrent portion of prepaid fleet leasing costs reclassified to Operating lease right-of-use assets. (c) Represents current portion of deferred rent and lease incentive liability reclassified to Operating lease liability. The adoption of the new leases standard did not January 1, 2019, In July 2017, 2017 11, Earnings Per Share (Topic 260 ), Distinguishing Liabilities from Equity (Topic 480 ), Derivatives and Hedging (Topic 815 ): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. 480 not December 15, 2018, 2017 11 January 1, 2019. 2017 11, March 31, 2019 January 1, 2019 ( 11 In June 2018, 2018 07, Compensation—Stock Compensation (Topic 718 2018 07 January 1, 2019, $2 In August 2018, 2018 13, Fair Value Measurement (Topic 820 December 15, 2019, not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]	(in thousands) March 31, December 31, 2019 2018 Cash and cash equivalents $ 2,932 $ 3,183 Restricted cash included in Other assets 475 475 Total cash, cash equivalents, and restricted cash in the statement of cash flows $ 3,407 $ 3,658
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Three Months Ended March 31, Major distribution or collaboration partner 2019 2018 Distributer A 26 % 21 % Distributer B 14 % 27 % Distributer C 17 % 25 % March 31, December 31, Major distribution or collaboration partner 2019 2018 Distributer A 41 % 32 % Distributer B 33 % 23 % Distributer C 13 % 31 %
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	(in thousands except per share) Three Months Ended March 31, Numerator 2019 2018 Net loss $ (4,189 ) $ (2,150 ) Less gain on changes in fair value of warrant liability — (214 ) Net loss, diluted $ (4,189 ) $ (2,364 ) Denominator Weighted average shares outstanding, basic 17,093 16,406 Net loss per share, basic $ (0.25 ) $ (0.13 ) Weighted average shares outstanding, basic 17,093 16,406 Effect of dilutive warrants — 264 Weighted average shares outstanding, diluted 17,093 16,670 Net loss per share, diluted $ (0.25 ) $ (0.14 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of March 31, (in thousands) 2019 2018 Period end stock options to purchase common stock 2,389 2,433 Period end common stock warrants 544 — 2,933 2,433
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Prepaid expenses and other current assets (a) $ (49 ) Operating lease right-of-use assets 2,239 Other assets (b) (2 ) Other accrued liabilities (c) (101 ) Operating lease liability 1,063 Deferred rent (184 ) Operating lease liability - non-current 1,410

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements Using (in thousands) Balance at March 31, 2019 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 103 $ 103 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 151 151 — — Total assets $ 578 $ 578 $ — $ — Liabilities Warrant liability $ 179 $ — $ — $ 179 Derivative liability 427 — — 427 Total liabilities $ 606 $ — $ — $ 606 Fair Value Measurements Using (in thousands) Balance at December 31, 2018 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 103 $ 103 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 151 151 — — Total assets $ 578 $ 578 $ — $ — Liabilities Warrant liability $ 178 $ — $ — $ 178 Total liabilities $ 178 $ — $ — $ 178
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Level 3 (in thousands) liabilities Balance at December 31, 2018 $ 178 Fair value of warrant liability reclass to equity-Adoption of ASU 2017-11 (56 ) Increase in fair value of warrant liability at March 31, 2019 57 Embedded derivative liability associated with the convertible note 427 Fair value of warrant liability and embedded derivative liability at March 31, 2019 $ 606

Note 4 - Prepaid Expenses and_2

Note 4 - Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	March 31, December 31, (in thousands) 2019 2018 Prepaid sales rebates $ 803 $ 925 Rent receivable 80 108 Prepaid rent — 130 Prepaid employees’ benefits 8 113 Prepaid dues and subscription 129 130 Inventory deposits 83 — Other 348 354 Total prepaid expenses and other current assets $ 1,451 $ 1,760

Note 5 - Inventory (Tables)

Note 5 - Inventory (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, December 31, (in thousands) 2019 2018 Raw materials and supplies $ 188 $ 217 Finished goods 224 167 Less: Reserve for excess and obsolete inventory (110 ) (104 ) Total inventory, net $ 302 $ 280

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, December 31, (in thousands) 2019 2018 Office and laboratory equipment $ 24 $ 24 Furniture and fixtures 157 157 Computer equipment and software 394 385 Production equipment 65 65 Leasehold improvements 79 79 Total property and equipment, at cost 719 710 Less: accumulated depreciation and amortization (526 ) (509 ) Total property and equipment, net $ 193 $ 201

Note 7 - Accrued Liabilities (T

Note 7 - Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, December 31, (in thousands) 2019 2018 Employee payroll and benefits $ 630 $ 708 Severance 124 — Avenova contract liabilities 1,816 2,282 Deferred rent — 101 Other 290 164 Total accrued liabilities $ 2,860 $ 3,255

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Lease, Cost [Table Text Block]	Lease Costs Operating lease cost $ 312 Sublease income (158 ) Net lease cost $ 154 Other information Operational cash flow used for operating leases $ 324 Weighted-average remaining lease term (in years) 2.2 Weighted-average discount rate 12 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Remaining in 2019 $ 970 2020 1,046 2021 438 2022 75 Thereafter — Total future minimum lease payments 2,529 Less imputed interest (313 ) Total $ 2,216 Reported as: Operating lease liability $ 1,073 Operating lease liability- non-current 1,143 Total $ 2,216
Lessor, Operating Lease, Payments to be Received, Maturity [Table Text Block]	Remaining in 2019 $ 566 2020 577 2021 — 2022 — Thereafter — Total future minimum lease payments $ 1,143

Note 9 - Related Party Notes _2

Note 9 - Related Party Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	(in thousands) Principle amount $ 1,000 Unamortized debt issuance costs (15 ) Accrued interst 34 Total debt 1,019 Less: short-term (1,019 ) Long-term $ —

Note 10 - Convertible Note (Tab

Note 10 - Convertible Note (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	As of Assumption March 26, 2019 Stock price (latest bid price) $ 1.28 Equity volatility 93.8 % Risk-free interest rate 2.34 % Remaining term 1.5
Convertible Debt [Table Text Block]	(in thousands) Principle amount $ 2,215 Unamortized discount (795 ) Unamortized debt issuance costs (193 ) Total debt 1,227 Less: short-term — Long-term $ 1,227
Schedule of Maturities of Long-term Debt [Table Text Block]	(in thousands) Remainder of 2019 $ — 2020 2,215 2021 and thereafter — Total $ 2,215

Note 11 - Warrant Liability (Ta

Note 11 - Warrant Liability (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Derivative Instruments [Table Text Block]	As of March 31, December 31, Assumption 2019 2018 Expected price volatility 104 % 77 % Expected term (in years) 0.93 1.18 Risk-free interest rate 2.41 % 2.60 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 0.45 $ 0.29 As of December 31, Assumption 2018 Expected price volatility 77 % Expected term (in years) 1.18 Risk-free interest rate 2.60 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 0.24 As of December 31, Assumption 2018 Expected price volatility 77 % Expected term (in years) 1.18 Risk-free interest rate 2.60 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 0.29 As of March 31, December 31, Assumption 2019 2018 Expected price volatility 93 % 73 % Expected term (in years) 1.58 1.83 Risk-free interest rate 2.33 % 2.51 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 0.55 $ 0.38
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Weighted- Average Exercise (in thousands) Warrants Price Outstanding at December 31, 2018 544 $ 1.81 Warrants granted — $ — Warrants exercised — $ — Warrants expired — $ — Outstanding at March 31, 2019 544 $ 1.81
July 2011, Long-term, Short-term, and October 2015 Warrants [Member]
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant Shares and dollars in thousands Shares Liability July 2011 Warrants 49 $ 23 October 2015 Warrants 284 156 333 $ 179

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Weighted- Average Exercise (in thousands) Warrants Price Outstanding at December 31, 2018 544 $ 1.81 Warrants granted — $ — Warrants exercised — $ — Warrants expired — $ — Outstanding at March 31, 2019 544 $ 1.81

Note 13 - Equity-based Compen_2

Note 13 - Equity-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	(in thousands, except years and per share data) Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2018 3,374 $ 4.13 8.2 $ 8 Restricted stock units vested (6 ) $ — Options forfeited/cancelled (978 ) $ 2.66 Restricted stock units cancelled (1 ) $ — Outstanding at March 31, 2019 2,389 $ 4.75 7.7 $ 6 Vested and expected to vest at March 31, 2019 2,355 $ 4.78 7.7 $ 5 Vested at March 31, 2019 1,725 $ 5.71 7.3 $ — Exercisable at March 31, 2019 1,725 $ 5.71 7.3 $ —
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, (in thousands) 2019 2018 Research and development $ 11 $ 7 Sales and Marketing 19 34 General and administrative 84 145 Total stock-based compensation expense $ 114 $ 186

Note 14 - License, Collaborat_2

Note 14 - License, Collaboration and Distribution Agreements (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Contract with Customer, Asset and Liability [Table Text Block]	Balance at Beginning of the Period Additions Deductions Balance at the end of the Period (in thousands) Contract Liabilities: Deferred Revenue $ 41 $ — $ (41 ) $ — Contract Liabilities: Accrued Liabilities 1,432 2,664 (3,029 ) 1,067 Total $ 1,473 $ 2,664 $ (3,070 ) $ 1,067
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2019 2018 Revenue recognized in the period from: Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 1,444 $ 1,439 New activities in the period: Performance obligations satisfied 47 1,508 $ 1,491 $ 2,947

Note 1 - Organization (Details

Note 1 - Organization (Details Textual)	Dec. 18, 2015	Mar. 31, 2019
Number of Operating Segments		4
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	25

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)$ / shares	Mar. 31, 2018USD ($)$ / shares	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Number of Major Distributors	3	3
Number of Major Source Manufacturers	2
Accounts Receivable, Allowance for Credit Loss, Ending Balance	$ 24			$ 10
Allowance for Doubtful Accounts, Past Due Period Threshold	120 days
Inventory Valuation Reserves, Ending Balance	$ 110			104
Operating Lease, Impairment Loss	$ 125
Impairment of Long-Lived Assets Held-for-use		$ 0
Payment for Product Supply Period	30 days
Additional Paid in Capital, Ending Balance	$ 120,484			119,764
Warrants and Rights Outstanding	$ 179			$ 178
Earnings Per Share, Basic, Total | $ / shares	$ (0.25)	$ (0.13)
Earnings Per Share, Diluted, Total | $ / shares	$ (0.25)	$ (0.14)
Accounting Standards Update 2017-01 [Member]
Additional Paid in Capital, Ending Balance	$ 56		$ 356
Warrants and Rights Outstanding	(56)
Accounting Standards Update 2017-01 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption			$ (356)
Accounting Standards Update 2018-07 [Member]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	$ 2
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	5 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	7 years
Computer Equipment and Software [Member]
Property, Plant and Equipment, Useful Life	3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life	7 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	7 years

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Cash and cash equivalents	$ 2,932	$ 3,183
Restricted cash included in Other assets	475	475
Total cash, cash equivalents, and restricted cash in the statement of cash flows	$ 3,407	$ 3,658	$ 8,810	$ 3,673

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable From Major Distribution Partners and Customers (Details) - Customer Concentration Risk [Member]	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Revenue from Contract with Customer Benchmark [Member] | Distributor A [Member]
distribution or collaboration partners	26.00%	21.00%
Revenue from Contract with Customer Benchmark [Member] | Distributor B [Member]
distribution or collaboration partners	14.00%	27.00%
Revenue from Contract with Customer Benchmark [Member] | Distributor C [Member]
distribution or collaboration partners	17.00%	25.00%
Accounts Receivable [Member] | Distributor A [Member]
distribution or collaboration partners	41.00%		32.00%
Accounts Receivable [Member] | Distributor B [Member]
distribution or collaboration partners	33.00%		23.00%
Accounts Receivable [Member] | Distributor C [Member]
distribution or collaboration partners	13.00%		31.00%

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Calculation of Basic and Diluted EPS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Net loss	$ (4,189)	$ (2,150)
Less gain on changes in fair value of warrant liability		(214)
Net loss, diluted	$ (4,189)	$ (2,364)
Weighted average shares outstanding, basic (in shares)	17,093	16,406
Net loss per share, basic (in dollars per share)	$ (0.25)	$ (0.13)
Effect of dilutive warrants (in shares)		264
Weighted average shares outstanding, diluted (in shares)	17,093	16,670
Net loss per share, diluted (in dollars per share)	$ (0.25)	$ (0.14)

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded From the Diluted Net Loss Per Share Computation (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Anti-dilutive stock options and stock warrants (in shares)	2,933	2,433
Share-based Payment Arrangement, Option [Member]
Anti-dilutive stock options and stock warrants (in shares)	2,389	2,433
Warrant [Member]
Anti-dilutive stock options and stock warrants (in shares)	544

Note 2 - Summary of Significa_8

Note 2 - Summary of Significant Accounting Policies - Impact of New Standard on Consolidated Balance Sheet (Details) - USD ($) $ in Thousands		Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Prepaid expenses and other current assets (a)		$ 1,451		$ 1,760
Operating lease right-of-use assets		1,870
Other assets (b)		542		552
Other accrued liabilities (c)		290		164
Operating lease liability		1,073
Deferred rent				184
Operating lease liability - non-current		$ 1,143
Accounting Standards Update 2016-02 [Member]
Prepaid expenses and other current assets (a)	[1]		$ (49)
Operating lease right-of-use assets			2,239
Other assets (b)	[2]		(2)
Other accrued liabilities (c)	[3]		(101)
Operating lease liability			1,063
Deferred rent			(184)
Operating lease liability - non-current			$ 1,410
[1]	Represents current portion of prepaid fleet leasing costs reclassified to Operating lease right-of-use assets.
[2]	Represents noncurrent portion of prepaid fleet leasing costs reclassified to Operating lease right-of-use assets.
[3]	Represents current portion of deferred rent and lease incentive liability reclassified to Operating lease liability.

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Jan. 01, 2019	Dec. 31, 2018
Class of Warrant or Right, Outstanding	544,000		334,109	544,000
Fair Value Adjustment of Warrants	$ 57	$ (214)
Accounting Standards Update 2017-11 [Member]
Warrants and Rights, Reclassified to Equity			210,586

Note 3 - Fair Value Measureme_4

Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Cash equivalents	$ 103	$ 103
Restricted cash held as a certificate of deposit	324	324
Deposit held as a certificate of deposit	151	151
Total assets	578	578
Warrant liability	179	178
Derivative liability	427
Total liabilities	606	178
Assets
Cash equivalents	103	103
Restricted cash held as a certificate of deposit	324	324
Deposit held as a certificate of deposit	151	151
Total assets	578	578
Liabilities
Warrant liability	179	178
Total liabilities	606	178
Fair Value, Inputs, Level 1 [Member]
Cash equivalents	103	103
Restricted cash held as a certificate of deposit	324	324
Deposit held as a certificate of deposit	151	151
Total assets	578	578
Warrant liability
Derivative liability
Total liabilities
Assets
Cash equivalents	103	103
Restricted cash held as a certificate of deposit	324	324
Deposit held as a certificate of deposit	151	151
Total assets	578	578
Liabilities
Warrant liability
Total liabilities
Fair Value, Inputs, Level 2 [Member]
Cash equivalents
Restricted cash held as a certificate of deposit
Deposit held as a certificate of deposit
Total assets
Warrant liability
Derivative liability
Total liabilities
Assets
Cash equivalents
Restricted cash held as a certificate of deposit
Deposit held as a certificate of deposit
Total assets
Liabilities
Warrant liability
Total liabilities
Fair Value, Inputs, Level 3 [Member]
Cash equivalents
Restricted cash held as a certificate of deposit
Deposit held as a certificate of deposit
Total assets
Warrant liability	179	178
Derivative liability	427
Total liabilities	606	178
Assets
Cash equivalents
Restricted cash held as a certificate of deposit
Deposit held as a certificate of deposit
Total assets
Liabilities
Warrant liability	179	178
Total liabilities	$ 606	$ 178

Note 3 - Fair Value Measureme_5

Note 3 - Fair Value Measurements - Fair Value of Warrant Liability (Details) - Warrant Liability [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Balance at December 31, 2018	$ 178
Fair value of warrant liability reclass to equity-Adoption of ASU 2017-11	(56)
Increase in fair value of warrant liability at March 31, 2019	57
Embedded derivative liability associated with the convertible note	427
Fair value of warrant liability and embedded derivative liability at March 31, 2019	$ 606

Note 4 - Prepaid Expenses and_3

Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Prepaid sales rebates	$ 803	$ 925
Rent receivable	80	108
Prepaid rent		130
Prepaid employees’ benefits	8	113
Prepaid dues and subscription	129	130
Inventory deposits	83
Other	348	354
Total prepaid expenses and other current assets	$ 1,451	$ 1,760

Note 5 - Inventory - Summary of

Note 5 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Raw materials and supplies	$ 188	$ 217
Finished goods	224	167
Less: Reserve for excess and obsolete inventory	(110)	(104)
Total inventory, net	$ 302	$ 280

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Depreciation, Depletion and Amortization, Total	$ 17	$ 41

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Property and equipment, at cost	$ 719	$ 710
Less: accumulated depreciation and amortization	(526)	(509)
Total property and equipment, net	193	201
Equipment [Member]
Property and equipment, at cost	24	24
Furniture and Fixtures [Member]
Property and equipment, at cost	157	157
Computer Equipment and Software [Member]
Property and equipment, at cost	394	385
Production Equipment [Member]
Property and equipment, at cost	65	65
Leasehold Improvements [Member]
Property and equipment, at cost	$ 79	$ 79

Note 7 - Accrued Liabilities -

Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Employee payroll and benefits	$ 630	$ 708
Severance	124
Avenova contract liabilities	1,816	2,282
Deferred rent		101
Other accrued liabilities (c)	290	164
Total accrued liabilities	$ 2,860	$ 3,255

Note 8 - Commitments and Cont_3

Note 8 - Commitments and Contingencies (Details Textual) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)
Operating Lease, Impairment Loss	$ 125
Master Fleet Lease Agreement [Member]
Number of Vehicles Leased	54
Lessee, Operating Lease, Term of Contract	3 years
KBSIII Towers [Member]
Lessee, Operating Lease, Renewal Term	5 years

Note 8 - Commitments and Cont_4

Note 8 - Commitments and Contingencies - Lease Expense (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Operating lease cost	$ 312
Sublease income	(158)
Net lease cost	154
Operational cash flow used for operating leases	$ 324
Weighted-average remaining lease term (in years) (Year)	2 years 73 days
Weighted-average discount rate	12.00%

Note 8 - Commitments and Cont_5

Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Remaining in 2019	$ 970
2020	1,046
2021	438
2022	75
Thereafter
Total future minimum lease payments	2,529
Less imputed interest	(313)
Total	2,216
Operating lease liability	1,073
Operating lease liability - non-current	1,143
Total	$ 2,216

Note 8 - Commitments and Cont_6

Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments to Be Received (Details) $ in Thousands	Mar. 31, 2019USD ($)
Remaining in 2019	$ 566
2020	577
2021
2022
Thereafter
Total future minimum lease payments	$ 1,143

Note 9 - Related Party Notes _3

Note 9 - Related Party Notes Payable (Details Textual) - USD ($) $ in Thousands	Feb. 27, 2019	Mar. 31, 2019
Pioneer Hong Kong [Member] | Promissory Note [Member]
Debt Instrument, Face Amount	$ 1,000
Debt Instrument, Periodic Payment, Interest	150
Debt Issuance Costs, Net, Total	$ 20
Interest Expense, Debt, Total		$ 39
China Kington [Member]
Brokering Fee, Percent	2.00%
Consulting Agreement, Term	1 year
Director Bob Wu [Member]
Consulting Agreement, Amount	$ 100

Note 9 - Related Party Notes _4

Note 9 - Related Party Notes Payable - Schedule of related Party Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Less: short-term	$ (1,019)
Pioneer Hong Kong [Member] | Secured Convertible Promissory Note [member]
Debt Instrument, Face Amount	1,000
Unamortized debt issuance costs	(15)
Accrued interst	34
Total debt	1,019
Less: short-term	(1,019)
Long-term

Note 10 - Convertible Note (Det

Note 10 - Convertible Note (Details Textual) - USD ($)	Mar. 26, 2019	Mar. 31, 2019	Mar. 31, 2018
Proceeds from Convertible Debt		$ 2,000,000
Embedded Derivative, Fair Value of Embedded Derivative Liability		427,000,000
Embedded Derivative, Fair Value Recorded as Additional Discount to Convertible Debt		184,000,000
Non-cash Loss on Derivative Liability		811,000,000
Iliad Research and Trading, L.P. [Member] | Secured Convertible Promissory Note [member]
Debt Instrument, Face Amount	$ 2,215,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Proceeds from Convertible Debt	$ 2,000,000
Debt Instrument, Original Issue Discount	200,000
Debt Instrument, Fee Amount	15,000
Deferred Finance Costs Excluding Transaction Fees	$ 182,000
Debt Instrument, Convertible, Conversion Price	$ 1.65
Debt Instrument, Convertible, Redeemed Amount Per Month	$ 200,000
Debt Instrument, Convertible, Market Price, Percentage of Lowest Closing Bid Price	85.00%
Debt Instrument, Redemption Price, Percentage	115.00%
Common Stock, Capital Shares Reserved for Future Issuance	3,200,000
Debt Instrument, Collateral Amount	$ 1,000,000
Debt Instrument, Convertible, Increase in Outstanding Balance, Percentage	15.00%
Debt Issuance Cost, Gross, Noncurrent		$ 197,000
Debt Instrument, Interest Rate, Effective Percentage	64.00%

Note 10 - Convertible Note - Ke

Note 10 - Convertible Note - Key Assumptions Used to Value the Combined Embedded Derivative (Details)	Mar. 31, 2019yr
Measurement Input, Share Price [Member]
Stock price (latest bid price)	0.0128
Measurement Input, Price Volatility [Member]
Stock price (latest bid price)	0.938
Measurement Input, Risk Free Interest Rate [Member]
Stock price (latest bid price)	0.0234
Measurement Input, Expected Term [Member]
Stock price (latest bid price)	1.5

Note 10 - Convertible Note - Sc

Note 10 - Convertible Note - Schedule of Convertible Note (Details) - Secured Convertible Promissory Note [member] - Iliad Research and Trading, L.P. [Member] $ in Thousands	Mar. 31, 2019USD ($)
Principle amount	$ 2,215
Unamortized discount	(795)
Unamortized debt issuance costs	(193)
Long-term	1,227
Less: short-term
Long-term	$ 1,227

Note 10 - Convertible Note - _2

Note 10 - Convertible Note - Schedule of Maturity of Convertible Note (Details) - Iliad Research and Trading, L.P. [Member] - Secured Convertible Promissory Note [member] $ in Thousands	Mar. 31, 2019USD ($)
Remainder of 2019
2020	2,215
2021 and thereafter
Total	$ 2,215

Note 11 - Warrant Liability (De

Note 11 - Warrant Liability (Details Textual) - USD ($) $ / shares in Units, $ in Thousands

Oct. 27, 2015

Oct. 27, 2015

Oct. 22, 2015

Mar. 03, 2015

Oct. 31, 2015

Jul. 31, 2011

Mar. 31, 2019

Jun. 30, 2017

Dec. 31, 2016

Sep. 30, 2016

Jan. 01, 2019

Dec. 31, 2018

Feb. 29, 2016

Mar. 31, 2015

Jan. 05, 2012

Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Warrants Issued

139,520

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 33.25

$ 1.81

$ 1.81

Minimum Common Stock Closing Bid Price Per Share

$ 66.50

Shares Issued, Price Per Share

$ 5

$ 5

Warrants and Rights Outstanding

$ 179

$ 178

Additional Paid in Capital, Ending Balance

$ 120,484

$ 119,764

Class of Warrant or Right, Exercised During Period

Accounting Standards Update 2017-11 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

3,613,284

Warrants and Rights Outstanding

$ (56)

Additional Paid in Capital, Ending Balance

$ 56

$ 356

Accounting Standards Update 2017-11 [Member] | Retained Earnings [Member]

Cumulative Effect of New Accounting Principle in Period of Adoption

$ (356)

Underwriting Agreement [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 5

$ 5

Warrants and Rights Outstanding, Term

5 years

5 years

Stock Issued During Period, Shares, New Issues

492,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

442,802

442,802

Shares Issued, Price Per Share

$ 5

$ 5

Proceeds from Issuance of Stock and Warrants

$ 2,100

Warrants and Rights Outstanding

1,300

$ 1,300

March 2015 Short-term and Long-term Warrants [Member]

Length of Notice for warrant Holders

20 days

2 days

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

21,000

Class of Warrant or Right, Exercised During Period

21,000

Proceeds from Warrant Exercises

$ 38

Warrant Liabilities, Fair Value Disclosure

58

Fair Market Value of Warrants Transferred to Equity Upon Exercise

$ 58

Short-term Warrants [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 15

Warrants and Rights Outstanding, Term

1 year 65 days

Short-term Warrants [Member] | Private Placement [Member]

Warrants and Rights Outstanding, Term

1 year 90 days

Long-term Warrants [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 16.25

Warrants and Rights Outstanding, Term

1 year 65 days

Long-term Warrants [Member] | Private Placement [Member]

Warrants and Rights Outstanding, Term

5 years

The 2011 and March 2015 Warrants [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 5

Class of Warrant or Right Price Protection Provision Exchangeable Securities Exercise Price Trigger

$ 5

Warrants and Rights Outstanding

$ 1,800

$ 1,800

July 2011, March 2015, and October 2015 Warrants [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 1.81

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

363,523

Class of Warrant or Right, Exercised During Period

363,523

3,613,284

Proceeds from Warrant Exercises

$ 900

$ 6,900

Warrant Liabilities, Fair Value Disclosure

500

1,600

Fair Market Value of Warrants Transferred to Equity Upon Exercise

$ 500

$ 1,600

Note 11 - Warrant Liability - T

Note 11 - Warrant Liability - The Key Assumptions Used to Value the Warrants (Details)	Mar. 31, 2019	Dec. 31, 2018
The 2011 Warrants [Member]
Warrants and Rights Outstanding, Term	339 days	1 year 65 days
Short-term Warrants [Member]
Warrants and Rights Outstanding, Term		1 year 65 days
Long-term Warrants [Member]
Warrants and Rights Outstanding, Term		1 year 65 days
Measurement Input, Price Volatility [Member] | The 2011 Warrants [Member]
Warrants assumptions	1.04	0.77
Measurement Input, Price Volatility [Member] | Short-term Warrants [Member]
Warrants assumptions		0.77
Measurement Input, Price Volatility [Member] | Long-term Warrants [Member]
Warrants assumptions		0.77
Measurement Input, Price Volatility [Member] | October 2015 Warrants [Member]
Warrants assumptions	0.93	0.73
Measurement Input, Risk Free Interest Rate [Member] | The 2011 Warrants [Member]
Warrants assumptions	0.0241	0.026
Measurement Input, Risk Free Interest Rate [Member] | Short-term Warrants [Member]
Warrants assumptions		0.026
Measurement Input, Risk Free Interest Rate [Member] | Long-term Warrants [Member]
Warrants assumptions		0.026
Measurement Input, Risk Free Interest Rate [Member] | October 2015 Warrants [Member]
Warrants assumptions	0.0233	0.0251
Measurement Input, Expected Dividend Rate [Member] | The 2011 Warrants [Member]
Warrants assumptions	0	0
Measurement Input, Expected Dividend Rate [Member] | Short-term Warrants [Member]
Warrants assumptions		0
Measurement Input, Expected Dividend Rate [Member] | Long-term Warrants [Member]
Warrants assumptions		0
Measurement Input, Expected Dividend Rate [Member] | October 2015 Warrants [Member]
Warrants assumptions	0	0
Measurement Input, Share Price [Member] | The 2011 Warrants [Member]
Warrants assumptions	0.0045	0.0029
Measurement Input, Share Price [Member] | Short-term Warrants [Member]
Warrants assumptions		0.0024
Measurement Input, Share Price [Member] | Long-term Warrants [Member]
Warrants assumptions		0.0029
Measurement Input, Share Price [Member] | October 2015 Warrants [Member]
Warrants assumptions	0.0055	0.0038
Measurement Input, Expected Term [Member] | October 2015 Warrants [Member]
Warrants assumptions	1.58	1.83

Note 11 - Warrant Liability - O

Note 11 - Warrant Liability - Outstanding Warrant Liability (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Shares (in shares)	544,000	334,109	544,000
Warrant liability	$ 179		$ 178
The 2011 Warrants [Member]
Shares (in shares)	49,000
Warrant liability	$ 23
October 2015 Warrants [Member]
Shares (in shares)	284,000
Warrant liability	$ 156
July 2011, Long-term, Short-term, and October 2015 Warrants [Member]
Shares (in shares)	333,000
Warrant liability	$ 179

Note 12 - Stockholders' Equit_2

Note 12 - Stockholders' Equity (Details Textual) - USD ($)	Mar. 29, 2019	Mar. 31, 2018	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018	Feb. 29, 2016	Jul. 31, 2011
Preferred Stock, Shares Authorized			5,000,000		5,000,000
Preferred Stock, Shares Outstanding, Ending Balance			0		0
Common Stock, Par or Stated Value Per Share			$ 0.01		$ 0.01
Stock Issued During Period, Value, New Issues		$ 5,984,000
Common Stock, Shares Authorized			50,000,000		240,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.81		$ 1.81		$ 33.25
Additional Paid in Capital, Ending Balance			$ 120,484,000		$ 119,764,000
Warrants and Rights Outstanding			179,000		$ 178,000
Retained Earnings [Member]
Stock Issued During Period, Value, New Issues
Accounting Standards Update 2017-11 [Member]
Warrants and Rights, Reclassified to Equity				210,586
Additional Paid in Capital, Ending Balance			56,000	$ 356,000
Warrants and Rights Outstanding			$ (56,000)
Accounting Standards Update 2017-11 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption				$ (356,000)
July 2011, March 2015, and October 2015 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 1.81
OP Financial Investments Limited [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues		1,700,000
Common Stock, Par or Stated Value Per Share		$ 0.01
Stock Issued During Period, Value, New Issues		$ 5,984,000
China Kington Asset Management Co. Ltd. [Member] | Private Placement [Member]
Private Placement, Commission Percentage		6.00%
Payments of Stock Issuance Costs		$ 359,040
NYSE American [Member] | Private Placement [Member]
Payments of Stock Issuance Costs		$ 34,000
Triton Funds LP [Member]
Common Stock, Shares Authorized	3,000,000
Purchase Price, Percentage of Lowest Trading Price of Common Stock for Five Days Prior to Closing	90.00%
Triton Funds LLC [Member]
Stock Issued During Period, Shares, New Issues	150,000

Note 12 - Stockholders' Equit_3

Note 12 - Stockholders' Equity - Outstanding Warrants (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Outstanding warrants (in shares) | shares	544
Outstanding warrants, weighted-average exercise price (in dollars per share) | $ / shares	$ 1.81
Warrants granted (in shares) | shares
Warrants granted, weighted average exercise price (in dollars per share) | $ / shares
Warrants exercised (in shares) | shares
Warrants exercised, weighted average exercise price (in dollars per share) | $ / shares
Warrants expired (in shares) | shares
Warrants expired, weighted average exercise price (in dollars per share) | $ / shares
Outstanding warrants (in shares) | shares	544
Outstanding warrants, weighted-average exercise price (in dollars per share) | $ / shares	$ 1.81

Note 13 - Equity-based Compen_3

Note 13 - Equity-based Compensation (Details Textual) - USD ($) $ in Thousands

May 26, 2016

Mar. 30, 2015

Mar. 30, 2018

Jan. 31, 2017

Jan. 31, 2016

Jan. 31, 2014

Jan. 31, 2013

Jan. 31, 2012

Jan. 31, 2011

Jan. 31, 2010

Mar. 31, 2019

Mar. 31, 2018

Jun. 30, 2016

Dec. 31, 2013

Dec. 31, 2012

Oct. 31, 2007

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value

$ 0

$ 5

Proceeds from Stock Options Exercised

0

$ 11

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

4,000

Share-based Payment Arrangement, Expense

114

$ 186

Payments of Dividends, Total

$ 0

Employees and Directors [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

0

0

Nonemployees [Member]

Share-based Payment Arrangement, Expense

$ 7

$ 7

Share-based Payment Arrangement, Option [Member]

Share-based Payment Arrangement, Expense

$ 107

$ 179

Share-based Payment Arrangement, Option [Member] | Mr. Liu [Member]

Share-based Payment Arrangement, Expense

$ 26

Share-based Compensation Arrangement by Share-based Payment Award, Exercisable Period

3 years

90 days

Share-based Payment Arrangement, Option [Member] | Nonemployees [Member]

Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued

0

0

Employee Stock Options and RSUs [Member]

Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total

$ 823

Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition

2 years 288 days

Restricted Stock Units (RSUs) [Member] | Employee [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

0

0

Restricted Stock [Member] | Nonemployees [Member]

Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued

0

0

The 2007 Omnibus Incentive Plan [Member]

Common Stock, Capital Shares Reserved for Future Issuance

40,000

Share-based Compensation Arrangement by Share-based Payment Award, Maximum Annual Increase in Shares Authorized

40,000

Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock

4.00%

4.00%

Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized

1,124,826

82,461

32,646

59,157

40,000

37,427

37,207

Increase (Decrease) in Number of Shares Available for Grant

610,774

139,449

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

2,318,486

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum

10.00%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

4 years

The 2007 Omnibus Incentive Plan [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

100.00%

The 2007 Omnibus Incentive Plan [Member] | Minimum [Member] | Shareholder of More Than 10% [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

110.00%

The 2007 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

The 2017 Omnibus Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock

4.00%

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

2,318,486

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

1,932,623

The 2017 Omnibus Incentive Plan [Member] | Incentive Stock Options (ISOs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum

10.00%

The 2017 Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

4 years

The 2017 Omnibus Incentive Plan [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

100.00%

The 2017 Omnibus Incentive Plan [Member] | Minimum [Member] | Shareholder of More Than 10% [Member] | Incentive Stock Options (ISOs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

110.00%

The 2017 Omnibus Incentive Plan [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

The 2017 Omnibus Incentive Plan [Member] | Maximum [Member] | Shareholder of More Than 10% [Member] | Incentive Stock Options (ISOs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

5 years

Note 13 - Equity-based Compen_4

Note 13 - Equity-based Compensation - Stock Options Outstanding (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Outstanding awards (in shares)	3,374
Outstanding, weighted-average exercise price (in dollars per share)	$ 4.75	$ 4.13
Outstanding, weighted-average remaining contractual life (Year)	7 years 255 days	8 years 73 days
Outstanding, aggregate intrinsic value	$ 6	$ 8
Options forfeited/cancelled (in shares)	(978)
Options forfeited/cancelled, weighted-average exercise price (in dollars per share)	$ 2.66
Outstanding awards (in shares)	2,389	3,374
Vested and expected to vest (in shares)	2,355
Vested and expected to vest, weighted-average exercise price (in dollars per share)	$ 4.78
Vested and expected to vest, weighted-average remaining contractual life (Year)	7 years 255 days
Vested and expected to vest, aggregate intrinsic value	$ 5
Vested (in shares)	1,725
Vested, weighted-average exercise price (in dollars per share)	$ 5.71
Vested, weighted-average remaining contractual life (Year)	7 years 109 days
Exercisable (in shares)	1,725
Exercisable, weighted-average exercise price (in dollars per share)	$ 5.71
Exercisable, weighted-average remaining contractual life (Year)	7 years 109 days
Restricted Stock Units (RSUs) [Member]
Restricted stock units vested (in shares)	(6)
Restricted stock units vested, weighted-average exercise price (in dollars per share)
Restricted stock units cancelled (in shares)	(1)

Note 13 - Equity-based Compen_5

Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Stock-based compensation expense	$ 114	$ 186
Research and Development Expense [Member]
Stock-based compensation expense	11	7
Selling and Marketing Expense [Member]
Stock-based compensation expense	19	34
General and Administrative Expense [Member]
Stock-based compensation expense	$ 84	$ 145

Note 14 - License, Collaborat_3

Note 14 - License, Collaboration and Distribution Agreements (Details Textual) - USD ($)

Jun. 01, 2013

Feb. 07, 2012

Apr. 30, 2013

Jan. 31, 2013

Oct. 31, 2012

Sep. 30, 2012

Jan. 31, 2012

Oct. 31, 2012

Mar. 31, 2019

Mar. 31, 2018

Dec. 31, 2014

Dec. 31, 2018

Contract with Customer, Liability, Total

$ 0

$ 41,000

Reallocated from Deferred Revenue [Member]

Stockholders' Equity, Period Increase (Decrease), Total

$ 600,000

China Pioneer [Member]

Proceeds from Issuance or Sale of Equity, Total

$ 2,500,000

Unit Purchase Agreement Shares Per Unit

1

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

1

Excess Fair Value Over Proceeds Received From Purchase

$ 1,000,000

China Pioneer [Member] | Tranche One [Member]

Purchase Agreement Units

800,000

China Pioneer [Member] | Tranche Two [Member]

Purchase Agreement Units

1,200,000

Purchase Agreement Unit Price Per Share

$ 1.25

Purchase Unit Agreement Total Units Fair Value

$ 3,500,000

China Pioneer [Member] | Neutrophase [Member]

Proceeds from Collaborators

$ 312,500

$ 312,500

$ 625,000

Maximum Possible Sales Discounts

$ 500,000

Integrated Healing Technologies, LLC [Member] | Neutrophase [Member]

Proceeds from Collaborators

$ 750,000

Virbac [Member] | Auriclosene (NVC-422) [Member]

Proceeds from Collaborators

$ 250,000

Principal Business Enterprise, Inc. [Member] | Neutrophase [Member]

Proceeds from Collaborators

$ 200,000

China Pioneer and Principal Business Enterprise Inc. [Member] | Samples and Future Products [Member]

Revenue, Remaining Performance Obligation, Amount

41,000

$ 13,000

McKesson Corporation [Member] | Avenova Product [Member]

Contract with Customer, Liability, Revenue Recognized

1,200,000

$ 2,600,000

McKesson Corporation [Member] | Avenova Product [Member] | Accounts Payable and Accrued Liabilities [Member]

Contract with Customer, Liability, Total

1,100,000

1,400,000

McKesson Corporation [Member] | Avenova Product [Member] | Prepaid Expenses and Other Current Assets [Member]

Contract with Customer, Rebate Liability, Current

$ 800,000

$ 900,000

Note 14 - License, Collaborat_4

Note 14 - License, Collaboration and Distribution Agreements - Changes in Assets and Liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Contract Liabilities: Deferred Revenue, Balance at beginning of the period	$ 41
Contract Liabilities: Deferred Revenue, additions
Contract Liabilities: Deferred Revenue, deductions	(41)
Contract Liabilities: Deferred Revenue, Balance at the end of the period
Contract Liabilities: Accrued Liabilities,Balance at beginning of the period	1,432
Contract Liabilities: Accrued Liabilities, additions	2,664
Contract Liabilities: Accrued Liabilities, deductions	(3,029)
Contract Liabilities: Accrued Liabilities, Balance at the end of the period	1,067
Contract Liabilities, Balance at beginning of the period	1,473
Contract Liabilities, additions	2,664
Contract Liabilities, deductions	(3,070)
Contract Liabilities, Balance at the end of the period	$ 1,067

Note 14 - License, Collaborat_5

Note 14 - License, Collaboration and Distribution Agreements - Total Revenues (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Total sales, net	$ 1,491	$ 2,947
Total sales, net	1,491	2,947
Transferred over Time [Member]
Total sales, net	1,444	1,439
Total sales, net	1,444	1,439
Transferred at Point in Time [Member]
Total sales, net	47	1,508
Total sales, net	$ 47	$ 1,508

Note 15 - Employee Benefit Pl_2

Note 15 - Employee Benefit Plan (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
The 401(k) Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0

Note 16 - Related Party Trans_2

Note 16 - Related Party Transactions (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Accounts Receivable, Related Parties	$ 6,000		$ 39,000
Related Party Transaction, Expenses from Transactions with Related Party	70,000	$ 359,000
China Pioneer [Member]
Revenue from Related Parties	41,000	13,000
China Pioneer [Member] | Selling and Marketing Expense [Member]
Related Party Costs	0	$ 219,000
China Kington [Member] | Broker Fee for Issuance of Promissory Note [Member]
Related Party Transaction, Expenses from Transactions with Related Party	20,000
China Kington [Member] | Interest Expense on Promissory Note [Member]
Related Party Transaction, Expenses from Transactions with Related Party	4,000
Director Bob Wu [Member] | Interest Expense on Promissory Note [Member]
Related Party Transaction, Expenses from Transactions with Related Party	8,000
Director Bob Wu [Member] | Consulting Fee Pursuant to Consulting Agreement [Member]
Related Party Transaction, Expenses from Transactions with Related Party	$ 50,000

Note 17 - Subsequent Events (De

Note 17 - Subsequent Events (Details Textual) - USD ($)	May 13, 2019	Mar. 29, 2019	Mar. 31, 2018	Apr. 22, 2019	Mar. 31, 2019	Dec. 31, 2018	Oct. 27, 2015
Common Stock, Shares Authorized					50,000,000	240,000,000
Shares Issued, Price Per Share							$ 5
Stock Issued During Period, Value, New Issues			$ 5,984,000
Subsequent Event [Member] | Triton Funds LP [Member] | Novabay Pharmaceuticals, Inc [Member]
Ownership Percentage Limitation				9.99%
Triton Funds LP [Member]
Common Stock, Shares Authorized		3,000,000
Purchase Price, Percentage of Lowest Trading Price of Common Stock for Five Days Prior to Closing		90.00%
Triton Funds LP [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues	1,747,312
Common Stock Purchase Agreement, Shares to Be Sold				1,747,312
Shares Issued, Price Per Share	$ 0.37089
Stock Issued During Period, Value, New Issues	$ 648,060.55
Triton Funds LLC [Member]
Stock Issued During Period, Shares, New Issues		150,000